3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
8
Leukemia, Myeloid, Chronic-Phase
6
Blast Crisis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Sarcoma
4
Melanoma
4
Gastrointestinal Stromal Tumors
4
Leukemia, Myeloid, Accelerated Phase
3
Sarcoma, Synovial
2
Oligodendroglioma
2
Leukemia, Myeloid, Acute
2
Glioma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Refractory Desmoplastic Small Round Cell Tumors
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Piebaldism
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neurofibromatoses
1
Interventions
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neurofibroma
×
Imatinib Mesylate
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts